{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T20:56:52Z","timestamp":1790542612956,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA139-83-01A1"],"award-info":[{"award-number":["R01CA139-83-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bneo.2026.100295","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T16:25:40Z","timestamp":1787934340000},"page":"100295","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["IMiD-based monotherapy for maintenance of remission in primary CNS lymphoma: a single-center experience"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8687-1514","authenticated-orcid":false,"given":"Michael P.","family":"Randall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazie","family":"Tsang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jazlynn","family":"Gee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8138-0647","authenticated-orcid":false,"given":"Chitoh","family":"Yung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Rubenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bneo.2026.100295_bib1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41572-023-00439-0","article-title":"Primary central nervous system lymphoma","volume":"9","author":"Ferreri","year":"2023","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"10.1016\/j.bneo.2026.100295_bib2","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/neuonc\/nox187","article-title":"The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades","volume":"20","author":"Mendez","year":"2018","journal-title":"Neuro Oncol"},{"issue":"10","key":"10.1016\/j.bneo.2026.100295_bib3","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1093\/neuonc\/nos207","article-title":"Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial Sloan-Kettering Cancer Center","volume":"14","author":"Welch","year":"2012","journal-title":"Neuro Oncol"},{"issue":"25","key":"10.1016\/j.bneo.2026.100295_bib4","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1200\/JCO.2012.46.9957","article-title":"Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202)","volume":"31","author":"Rubenstein","year":"2013","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.bneo.2026.100295_bib5","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1038\/s41375-022-01582-5","article-title":"Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial","volume":"36","author":"Ferreri","year":"2022","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.bneo.2026.100295_bib6","doi-asserted-by":"crossref","first-page":"e796","DOI":"10.1093\/oncolo\/oyae059","article-title":"Clinical outcomes of etoposide and cytarabine as consolidation in elderly patients with primary CNS lymphoma","volume":"29","author":"Kim","year":"2024","journal-title":"Oncologist"},{"issue":"12","key":"10.1016\/j.bneo.2026.100295_bib7","doi-asserted-by":"crossref","first-page":"1191.e1","DOI":"10.1016\/j.jtct.2024.09.015","article-title":"Comparison of thiotepa-based conditioning regimens for older adults with primary diffuse large B-cell lymphoma of the central nervous system undergoing autologous hematopoietic cell transplantation","volume":"30","author":"Akhtar","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"10.1016\/j.bneo.2026.100295_bib8","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1200\/JCO.1998.16.3.859","article-title":"Long-term survival in primary CNS lymphoma","volume":"16","author":"Abrey","year":"1998","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.bneo.2026.100295_bib9","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1001\/archneur.62.10.1595","article-title":"Delayed neurotoxicity in primary central nervous system lymphoma","volume":"62","author":"Omuro","year":"2005","journal-title":"Arch Neurol"},{"issue":"6","key":"10.1016\/j.bneo.2026.100295_bib10","doi-asserted-by":"crossref","first-page":"e251","DOI":"10.1016\/S2352-3026(15)00074-5","article-title":"Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial","volume":"2","author":"Omuro","year":"2015","journal-title":"Lancet Haematol"},{"issue":"6","key":"10.1016\/j.bneo.2026.100295_bib11","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1200\/JCO.2003.03.036","article-title":"Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07","volume":"21","author":"Batchelor","year":"2003","journal-title":"J Clin Oncol"},{"issue":"3-4","key":"10.1016\/j.bneo.2026.100295_bib12","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/sj.bjc.6690083","article-title":"Second-line treatment for primary central nervous system lymphoma","volume":"79","author":"Reni","year":"1999","journal-title":"Br J Cancer"},{"issue":"13","key":"10.1016\/j.bneo.2026.100295_bib13","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/bloodadvances.2017014845","article-title":"Phase 1 investigation of lenalidomide\/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma","volume":"2","author":"Rubenstein","year":"2018","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.bneo.2026.100295_bib14","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/annonc\/mdz032","volume":"30","author":"Ghesquieres","year":"2019","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.bneo.2026.100295_bib15","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/bjh.15787","article-title":"Low-dose lenalidomide maintenance after induction therapy in older patients with primary central nervous system lymphoma","volume":"186","author":"Vu","year":"2019","journal-title":"Br J Haematol"},{"issue":"22","key":"10.1016\/j.bneo.2026.100295_bib16","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1200\/JCO.2005.13.524","article-title":"Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma","volume":"23","author":"Abrey","year":"2005","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.bneo.2026.100295_bib17","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s11060-014-1370-0","article-title":"Methotrexate re-challenge for recurrent primary central nervous system lymphoma","volume":"117","author":"Pentsova","year":"2014","journal-title":"J Neurooncol"},{"issue":"17","key":"10.1016\/j.bneo.2026.100295_bib18","doi-asserted-by":"crossref","first-page":"5643","DOI":"10.1158\/1078-0432.CCR-04-0159","article-title":"Treatment of relapsed central nervous system lymphoma with high-dose methotrexate","volume":"10","author":"Plotkin","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2026.100295_bib19","doi-asserted-by":"crossref","first-page":"4502.4","DOI":"10.1182\/blood-2024-209238","article-title":"Trial in progress - alliance A051901 - phase I trial of methotrexate, rituximab, lenalidomide, and nivolumab (Nivo-MR2) induction followed by lenalidomide and nivolumab maintenance in primary central nervous system lymphoma (PCNSL)","volume":"144","author":"Alencar","year":"2024","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bneo.2026.100295_bib20","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/bloodadvances.2024014460","article-title":"Identification of genomic biomarkers of disease progression and survival in primary CNS lymphoma","volume":"9","author":"Geng","year":"2025","journal-title":"Blood Adv"},{"issue":"14","key":"10.1016\/j.bneo.2026.100295_bib21","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/bloodadvances.2020002064","article-title":"High-dose chemotherapy and autologous stem cell transplant in elderly patients with primary CNS lymphoma: a pilot study","volume":"4","author":"Schorb","year":"2020","journal-title":"Blood Adv"},{"issue":"suppl 16","key":"10.1016\/j.bneo.2026.100295_bib22","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1200\/JCO.2024.42.16_suppl.2006","article-title":"A pilot study of axicabtagene ciloleucel (axi-cel) for relapsed\/refractory primary and secondary central nervous system lymphoma (PCNSL and SCNSL)","volume":"42","author":"Nayak","year":"2024","journal-title":"Journal of Clinical Oncology"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026001068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026001068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T20:07:45Z","timestamp":1790539665000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328026001068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2950328026001068"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100295","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IMiD-based monotherapy for maintenance of remission in primary CNS lymphoma: a single-center experience","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100295","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100295"}}